A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Eisai GmbH
- Target Recruit Count
- 187
- Registration Number
- NCT04202159
- Locations
- π©πͺ
Eisai Trial Site #15, Bernau, Germany
π©πͺEisai Trial Site #8, Bielefeld, Germany
π©πͺEisai Trial Site #9, Bonn, Germany
ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions
Completed
- Conditions
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eisai GmbH
- Target Recruit Count
- 246
- Registration Number
- NCT03082222
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- Eisai GmbH
- Target Recruit Count
- 353
- Registration Number
- NCT03027245
- Locations
- π©πͺ
Eisai Trial Site 2, Stuttgart, Germany
π©πͺEisai Trial Site 3, Munchen, Germany
π©πͺEISAI Trial Site 1, Dresden, Germany
Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Eisai GmbH
- Target Recruit Count
- 157
- Registration Number
- NCT00165828
- Locations
- π©πͺ
Epilepsieklinik Tabor, Bernau, Brandenburg, Germany
π©πͺInstitut fur Diagnostik der Epilepsien Gmbh, Berlin, Germany
π©πͺKlinik Ernst von Bergmann, Potsdam, Germany
Β© Copyright 2024. All Rights Reserved by MedPath